All forecasts
·Forecast · GLP-1 / MetabolicLive · 155d to resolution

Medicare GLP-1 Bridge

medicare-glp1-bridge-uptake

Current probability
66%
was 65% at creation
Last move
0
29 Jul 2026
Resolves
31 Dec 2026
in 155d
Signal strength
61
0–1000 composite score
I

The prediction

CMS reports fewer than 1,000,000 Medicare GLP-1 Bridge enrollees by 2026-12-31 (per official CMS Part D enrollment data)

Base rate: new Medicare Part D programs enroll slowly in year one (10-15% of eligible). 1M = ~7% of 14M eligible. Launches July 1 2026, so only 6 months of enrollment window in 2026. Friction factors: physician re-prescribing, formulary navigation, step therapy. Counter-narrative ~35%: aggressive CMS outreach + pent-up demand drives faster-than-normal uptake. Resolves on CMS public enrollment data release (usually Q1 following year).

II

Trajectory

  1. 18 April 2026 · created
    65%
    signal strength 55

    Base rate: new Medicare Part D programs enroll slowly in year one (10-15% of eligible). 1M = ~7% of 14M eligible. Launches July 1 2026, so only 6 months of enrollment window in 2026. Friction factors: physician re-prescribing, formulary navigation, step therapy. Counter-narrative ~35%: aggressive CMS outreach + pent-up demand drives faster-than-normal uptake. Resolves on CMS public enrollment data release (usually Q1 following year).

  2. 2026-04-19 07:00 UTC · Ra run
    65%
    0
    · signal 55

    First meaningful data comes late Q3 post-launch. Holding.

    Counter-narrative

    No new CMS rulemaking or enrollment data ahead of July 1 launch

  3. 2026-04-22 04:04 UTC · Ra runread brief →
    67%
    +0.02
    · signal 56

    Program details confirmed: operates outside Part D benefit, $50 copay does not count toward deductible or $2,100 OOP cap, Part D sponsors not directly involved. These structural details add friction: no sponsor marketing push, confusing benefit structure, physician re-prescribing required. Augur flags Medicaid BALANCE Model launching May 2026 as potential leading indicator for Medicare uptake patterns.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries + aggressive CMS outreach could drive >1M enrollees faster than historical Medicare program base rates

  4. 2026-04-22 10:52 UTC · Ra runread brief →
    67%
    0
    · signal 56

    Second-pass (10:52 UTC). AMCP FAQ confirms operational readiness. Foundayo listed alongside Wegovy/Zepbound as eligible — new branded GLP-1 broadens formulary.

    Counter-narrative

    Pent-up demand plus $50 copay for $1000+ drug overwhelms structural friction; BALANCE Model transition creates enrollment urgency

  5. 2026-04-22 15:30 UTC · Ra runread brief →
    67%
    0
    · signal 56

    BALANCE Model Medicaid launching May 2026 is the key leading indicator — watch enrollment data. Bridge extended through Dec 2027, possibly signaling CMS expects slow initial uptake. Central processor mechanism confirmed, adding friction. No enrollment data yet. Holding.

    Counter-narrative

    Pent-up demand + $50 copay vs $1000+ market price overwhelms structural friction; BALANCE Medicaid learning in May-June accelerates Medicare Bridge uptake

  6. 2026-04-23 07:04 UTC · Ra runread brief →
    67%
    0
    · signal 56

    No enrollment data — program starts July 1. Extension to Dec 2027 suggests CMS anticipates slow ramp. Three eligible medications confirmed. Holding.

    Counter-narrative

    Pent-up demand among eligible beneficiaries overwhelms structural friction as $50 copay for $1000 drug is too compelling

  7. 2026-04-24 07:04 UTC · Ra runread brief →
    68%
    +0.01
    · signal 57

    Health insurers balking at Medicare obesity drug coverage adds friction. Part D sponsors have no marketing incentive for Bridge. Foundayo addition broadens formulary but does not change structural friction. Extension to Dec 2027 confirms slow-ramp expectation.

    Counter-narrative

    Pent-up demand among eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  8. 2026-04-25 07:04 UTC · Ra runread brief →
    68%
    0
    · signal 56

    Foundayo oral option already priced in from prior runs. BALANCE Model Medicaid launch in May is next leading indicator. No enrollment data until post-July 1 launch. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as oral GLP-1 option removes injection barrier

  9. 2026-04-26 07:04 UTC · Ra runread brief →
    70%
    +0.02
    · signal 58

    CMS delayed Part D portion of BALANCE Model (AHA April 22). Implementation friction signal — same agency same drug class. Confirms slow-ramp thesis. Prior authorization required. Extension to Dec 2027 signals CMS expects slow uptake. +0.02.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  10. 2026-04-27 07:04 UTC · Ra runread brief →
    70%
    0
    · signal 58

    Weekly review: program details crystallized ($245/mo, $50 copay not toward OOP cap, prior auth, Foundayo+Wegovy+Zepbound KwikPen eligible). BALANCE delay confirmed. Extension to Dec 2027 signals slow ramp. Week's +0.03 properly captured. No enrollment data until post-July 1. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  11. 2026-04-28 04:04 UTC · Ra runread brief →
    70%
    0
    · signal 58

    Foundayo Week 2 Rx gap vs Wegovy oral is indirect friction signal but net neutral on Bridge enrollment. No pre-launch enrollment data. July 1 start in 64 days. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  12. 2026-04-29 07:04 UTC · Ra runread brief →
    70%
    0
    · signal 58

    ACHIEVE-4 published April 16 missed by prior runs: 57% lower all-cause death HR 0.43 in Foundayo vs insulin glargine over 104 weeks. Second-order catalyst for Bridge but bottleneck remains structural enrollment friction not physician confidence. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus ACHIEVE-4 cardiovascular data increases physician prescribing confidence overwhelming structural enrollment friction

  13. 2026-04-30 07:04 UTC · Ra runread brief →
    70%
    0
    · signal 58

    62 days to July 1 launch. No new enrollment data. Obesity Action Coalition outreach confirms advocacy readiness. Structural friction unchanged ($245/mo, $50 copay not toward OOP cap, prior auth, central processor). Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  14. 2026-05-01 07:04 UTC · Ra runread brief →
    72%
    +0.02
    · signal 59

    BALANCE Model Part D pilot CANCELED not delayed (STAT/Axios April 21-22) due to insurer pushback. Bridge is now the ONLY Medicare GLP-1 obesity pathway through Dec 2027. Centene confirmed participation. Removes more-efficient-program upside scenario. +0.02 strengthening under-1M thesis.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling and Centene MA-plan marketing drives awareness

  15. 2026-05-02 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 58

    FDA 503B GLP-1 exclusion further restricts compounded alternatives pushing more patients toward branded drugs and official channels. Second-order positive for Bridge demand but structural friction unchanged. 60 days to July 1 launch. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug overwhelms structural friction and 503B exclusion accelerates branded-only pathway

  16. 2026-05-03 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 58

    59 days to July 1 launch. CMS promised spring 2026 additional design info — nothing materialized. Operational silence at T-59 weakly correlates with slow-ramp launches per historical base rates. Humana confirmed as central processor. No enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  17. 2026-05-04 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 58

    58 days to July 1 launch. CMS still silent on spring 2026 operational guidance. Foundayo Week 3: 5,612 Rx (trajectory 1,390-3,707-5,612). Oral option broadens Bridge demand but structural friction unchanged. BALANCE Medicaid May launch is next data point. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus oral GLP-1 option overwhelms structural friction and $50 copay for $1000+ drug is too compelling

  18. 2026-05-05 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 58

    57 days to July 1 launch. CMS operational silence continues. Humana LI NET central processor confirmed. No pre-launch enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries overwhelms structural friction as $50 copay for $1000+ drug is too compelling

  19. 2026-05-06 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 58

    56 days to July 1 launch. CMS operational silence continues — spring 2026 design details promised but undelivered. Bridge eligibility confirmed: Foundayo Wegovy injection Wegovy oral Zepbound KwikPen. No enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug overwhelms structural friction

  20. 2026-05-07 07:04 UTC · Ra runread brief →
    71%
    -0.01
    · signal 59

    NPR May 6 consumer explainer is first mass-media coverage of Bridge program. NPR audience skews older toward Medicare-eligible demographic. Awareness accelerant but structural friction unchanged ($50 not toward OOP cap, prior auth, central processor, no Part D sponsor marketing). Modest -0.01.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus NPR mass-media awareness plus $50 copay for $1000+ drug overwhelms structural friction

  21. 2026-05-08 07:04 UTC · Ra runread brief →
    71%
    0
    · signal 59

    54 days to July 1 launch. CMS MLN Connects May 7 published but content inaccessible. Spring 2026 operational guidance still promised but undelivered. Cumulative friction signal escalating. Setting May 31 trigger for formal reassessment. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug overwhelms structural friction

  22. 2026-05-09 07:04 UTC · Ra runread brief →
    72%
    +0.01
    · signal 60

    53 days to July 1 launch. CMS published FAQ. AMCP + Reed Smith implementation analyses confirm $245/mo with $50 copay NOT counting toward Part D OOP cap — structural friction halving typical first-year Part D add-on enrollment. Foundayo Wegovy KwikPen Zepbound formulations confirmed eligible. NCPA flags May 11 CMS website update. Information landscape filling with friction-reinforcing details. +0.01 toward fewer-than-1M.

    Counter-narrative

    CMS launches aggressive enrollment campaign with insurer cooperation and pent-up obesity demand drives faster-than-typical first-year uptake

  23. 2026-05-10 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    52 days to July 1 launch. NCPA flags CMS website update May 11. Structural friction ($50 copay not toward OOP cap) confirmed. Spring operational guidance still undelivered. Holding pending May 11 CMS update.

    Counter-narrative

    CMS launches aggressive enrollment campaign and pent-up demand overwhelms structural friction

  24. 2026-05-11 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    51 days to July 1 launch. Humana confirmed as central processor via LI-NET. US News mainstream explainer May 8. Structural friction ($50 copay not toward OOP cap) confirmed. Spring operational guidance still undelivered. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus Humana LI-NET infrastructure enables faster-than-modeled enrollment

  25. 2026-05-12 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    50 days to July 1 launch. CMS website updated May 11 per NCPA. Structural friction confirmed. Spring operational guidance still undelivered. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus Humana LI-NET infrastructure enables faster-than-modeled enrollment

  26. 2026-05-13 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    49 days to July 1. Novo Nordisk PR formally marketing Wegovy Bridge inclusion — first pharma manufacturer to actively promote. NPR national explainer May 6. Both increase demand awareness but structural friction unchanged. Holding.

    Counter-narrative

    Pent-up demand plus Novo active marketing plus NPR national explainer enables faster-than-modeled enrollment exceeding 1M

  27. 2026-05-14 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    48 days to July 1. No new CMS operational guidance. Structural friction unchanged. Novo marketing and NPR explainer already priced in. Holding.

    Counter-narrative

    Pent-up demand plus Novo marketing plus NPR explainer enables faster-than-modeled enrollment exceeding 1M

  28. 2026-05-15 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    47 days to July 1. AMCP FAQ and Obesity Action Coalition materials are demand-infrastructure signals. Spring CMS operational guidance still undelivered. Structural friction unchanged. Holding.

    Counter-narrative

    Pent-up demand plus Novo marketing plus AMCP operational FAQ plus Obesity Action Coalition education enables faster-than-modeled enrollment exceeding 1M

  29. 2026-05-16 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 60

    46 days to July 1. CMS confirms pharmacies no-opt-in BIN 028918 PCN MEDDGLP1BR central-processor reimbursement at WAC plus dispensing fee. Operational rails hardening. BUT Zepbound vial and single-dose pen EXCLUDED — only KwikPen eligible — narrows practical Zepbound patient pool. Demand infra plus drug eligibility narrowed minus. Net hold.

    Counter-narrative

    Pent-up demand plus Novo marketing plus AMCP FAQ plus operational rail completion enables faster-than-modeled enrollment exceeding 1M

  30. 2026-05-17 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    45 days to launch. NPR May 6 piece is the most consequential mainstream awareness signal yet. Humana confirmed central processor. Zepbound vial/single-dose pen still excluded (KwikPen only) narrowing eligibility. Awareness up, eligibility narrowed, net flat.

    Counter-narrative

    NPR mainstream awareness plus Humana LI NET central-processor operational rails could drive aggressive uptake exceeding the 1M threshold; counter requires sustained ~165k/month enrollment over 6 months

  31. 2026-05-18 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    44 days to July 1. ABC News GMA and MMM-Online are the latest mainstream outlets covering Bridge. Demand awareness infrastructure building. Structural friction unchanged (PA mandatory, narrow drug list, $50 not toward OOP). Premortem this week: if CMS drops PA in June guidance, demand rails already primed for surge. Holding.

    Counter-narrative

    Pent-up demand plus aggressive mainstream media education plus Novo marketing enables faster-than-modeled enrollment exceeding 1M by Dec 31

  32. 2026-05-19 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    43 days to July 1. Novo Q1 sales up 32% CC Wegovy 65% of new US Rx. No new CMS operational guidance. Structural friction unchanged. Holding.

    Counter-narrative

    Pent-up demand plus Novo active marketing plus mainstream awareness enables faster-than-modeled enrollment exceeding 1M

  33. 2026-05-20 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    42 days to July 1 launch. Spring 2026 CMS operational guidance still undelivered at T-42. CMS silence accumulates. Structural friction unchanged. Mainstream awareness building but operational rails not advancing. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus NPR mainstream awareness plus Novo active marketing enables faster-than-modeled enrollment exceeding 1M

  34. 2026-05-21 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    41 days to July 1 launch. CMS operational silence continues at T-41 — spring 2026 guidance still undelivered. Mainstream awareness building but structural friction unchanged. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug overwhelms structural friction and mainstream media education drives enrollment past 1M

  35. 2026-05-22 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    40 days to July 1 launch. CMS operational silence continues at T-40 — spring 2026 guidance still undelivered. TRIUMPH-1 retatrutide not Bridge-eligible (not approved). Structural friction unchanged. No enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  36. 2026-05-23 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    39 days to July 1 launch. CMS operational silence continues at T-39 — spring 2026 guidance still undelivered. Foundayo Week 6 ~17K Rx confirms branded demand but does not touch Bridge enrollment mechanics. Structural friction unchanged. No enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  37. 2026-05-24 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    38 days to July 1 launch. CMS operational silence at T-38 — spring 2026 guidance still undelivered. Medicare programs that don't publish operational guidance by T-30 tend to have rougher first-quarter enrollment. Structural friction unchanged. No enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  38. 2026-05-26 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    36 days to July 1 launch. CMS operational silence at T-36 — spring 2026 guidance still undelivered. SavingAdvice May 25 first personal-finance outlet to cover Bridge. Audience segmentation widening but structural friction unchanged. T-30 formal reassessment trigger set for June 1. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream and personal-finance media awareness drives enrollment past 1M by Dec 31

  39. 2026-05-27 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    35 days to July 1 launch. CMS Spring 2026 guidance promise has 24 days left before calendar spring ends. Pharmacies need claims-processing configuration. T-30 formal reassessment trigger June 1 in 5 days. If no guidance by then upgrade to 0.75. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream and personal-finance media awareness drives enrollment past 1M by Dec 31

  40. 2026-05-28 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    34 days to July 1 launch. CMS Spring 2026 operational guidance still undelivered at T-34. T-30 formal reassessment trigger June 1 in 4 days. If no CMS pharmacy claims-processing guidance by then upgrade to 0.75. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  41. 2026-05-29 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    33 days to July 1 launch. CMS Spring 2026 operational guidance still undelivered at T-33. T-30 formal reassessment trigger activates June 1 in 3 days. BIN/PCN 028918 MEDDGLP1BR established Humana confirmed. If no guidance by June 1 upgrade to 0.75 per commitment. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  42. 2026-05-30 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    32 days to July 1 launch. CMS operational guidance still undelivered at T-32. T-30 formal reassessment trigger activates June 1 in 2 days. If no guidance by then upgrade to 0.75. Holding per commitment.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  43. 2026-05-31 07:04 UTC · Ra runread brief →
    72%
    0
    · signal 55

    31 days to July 1 launch. CMS operational guidance still undelivered at T-31. T-30 reassessment trigger fires TOMORROW June 1. Per pre-commitment: if no pharmacy claims-processing guidance by end of June 1 upgrade 0.72 to 0.75. Holding today per commitment schedule.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  44. 2026-06-01 07:04 UTC · Ra runread brief →
    75%
    +0.03
    · signal 56

    T-30 reassessment trigger fires today. CMS has NOT released pharmacy claims-processing guidance or prior auth fax form at T-30; promised in June 2026. BALANCE pilot canceled. Bridge is ONLY Medicare GLP-1 pathway through Dec 2027. Per pre-commitment upgrading 0.72 to 0.75. Next reassessment T-15 June 16 — if no guidance escalate to 0.78.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus June guidance delivery accelerates pharmacy readiness driving enrollment past 1M by Dec 31

  45. 2026-06-02 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    29 days to July 1 launch. CMS provider page now promises prior auth form in June 2026. 503B GLP-1 comment period closes June 29 same window as PCAC oral presentations. Moved to 0.75 yesterday on T-30 trigger. Next reassessment T-15 June 16. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus June guidance delivery accelerates pharmacy readiness driving enrollment past 1M by Dec 31

  46. 2026-06-03 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    BIN 028918 PCN MEDDGLP1BR published — pharmacies can configure claims systems. Prior auth fax form still not released at T-28. Operational infrastructure advancing while clinical authorization lags. T-15 reassessment June 16. Holding per commitment.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus ADA physician education wave drives enrollment past 1M by Dec 31

  47. 2026-06-04 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    T-27 to July 1 launch. BIN 028918 PCN MEDDGLP1BR confirmed. Prior auth fax form still not released. Spring 2026 guidance deadline ends June 20. ADA ACHIEVE-3 data tomorrow is demand-side catalyst in supply-side-constrained channel. T-15 reassessment June 16. Holding per commitment.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus ADA physician education wave drives enrollment past 1M by Dec 31

  48. 2026-06-05 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    T-26 to July 1 launch. Prior auth fax form still promised in June 2026 but not released. CMS Spring 2026 guidance deadline ends June 20. BIN 028918 PCN MEDDGLP1BR confirmed. ADA ACHIEVE-3 data Monday is demand-side catalyst in supply-side-constrained channel. T-15 reassessment June 16. Holding per pre-commitment schedule.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus ADA physician education wave drives enrollment past 1M by Dec 31

  49. 2026-06-06 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    T-25 to July 1 launch. Prior auth form still not released. CMS Spring 2026 guidance deadline ends June 20 in 14 days. ACHIEVE-3 Lancet publication confirms Foundayo 73.6% greater weight loss vs oral semaglutide at 52 weeks but 2x discontinuation rate — demand-side catalyst in supply-constrained channel. Discontinuation signal is new: 8.7-9.7% vs 4.5-4.9% for semaglutide could dampen Foundayo-specific prescribing. Next reassessment T-15 June 16. Holding per pre-commitment.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus ADA ACHIEVE-3 data showing Foundayo superiority drives physician prescribing past structural enrollment friction

  50. 2026-06-07 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    Weekly review. T-24 to July 1 launch. Prior auth form still not released. CMS Spring 2026 deadline ends June 20 in 13 days. ACHIEVE-3 Foundayo superiority confirmed but 2x discontinuation rate counterweight. Stoic: CMS timing unactionable. Next reassessment T-15 June 16. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media education drives enrollment past 1M by Dec 31

  51. 2026-06-08 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 56

    Weekly review. T-23 to July 1 launch. Prior auth form still not released. CMS Spring 2026 guidance deadline ends June 20 in 12 days. Wegovy pill 3M Rx in 5 months demonstrates explosive retail demand but Bridge operates on different rail with higher structural friction. Demand is not the binding constraint — enrollment process is. T-15 reassessment June 16. Per pre-commitment: if no prior auth form by June 16 upgrade to 0.78. Stoic: ACTIONABLE pre-position Bridge content. Holding per commitment schedule.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus Wegovy pill 3M Rx mainstream momentum drives enrollment past 1M by Dec 31

  52. 2026-06-09 07:04 UTC · Ra runread brief →
    73%
    -0.02
    · signal 58

    T-22 to July 1 launch. MATERIAL: CMS released prior auth form (cms.gov/glp-1-bridge.pdf) revealing clinical criteria — OSA MASH T2D or CVD required. Form breaks operational-silence escalation path; T-15 upgrade to 0.78 CANCELED. One friction barrier removed (form exists) modestly offset by clinical criteria narrowing eligible population. CNBC frames Novo/Lilly Medicare pill competition increasing awareness. Net -0.02. Next reassessment T-15 June 16.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus prior auth form availability plus mainstream media awareness drives enrollment past 1M by Dec 31

  53. 2026-06-10 07:04 UTC · Ra runread brief →
    73%
    0
    · signal 58

    T-21 to July 1 launch. CVS Foundayo coverage from June 1 and Zepbound by October expands commercial insurance access broadly — tangential to Bridge but signals shrinking pool of beneficiaries who need Bridge as only pathway. Prior auth form released June 9 (captured yesterday). Next reassessment T-15 June 16 per pre-commitment. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus prior auth form availability plus mainstream media awareness drives enrollment past 1M by Dec 31

  54. 2026-06-11 07:04 UTC · Ra runread brief →
    73%
    0
    · signal 58

    T-20 to July 1 launch. Prior auth form released June 9 captured in prior run. No new operational evidence today. T-15 reassessment pre-committed for June 16 in 5 days. Holding per pre-commitment schedule.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus prior auth form availability plus mainstream media awareness drives enrollment past 1M by Dec 31

  55. 2026-06-12 07:04 UTC · Ra runread brief →
    73%
    0
    · signal 58

    T-19 to July 1 launch. NCOA and Medicare Rights Center both confirm program details in consumer-facing guides — awareness infrastructure building. Prior auth form live since June 9. Bridge confirmed as weight-management-only pathway (comorbid patients route to Part D). Pre-committed T-15 reassessment June 16 in 4 days. Holding per commitment schedule.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus prior auth form availability plus mainstream media awareness drives enrollment past 1M by Dec 31

  56. 2026-06-13 07:04 UTC · Ra runread brief →
    73%
    0
    · signal 58

    T-18 to July 1 launch. CMS confirms beneficiaries NOT required to register or opt-in reducing one friction barrier. But prior auth via Humana central processor remains structural bottleneck. Bridge confirmed as weight-management-only pathway; comorbid patients route to Part D narrowing eligible population beyond headline 14M. Pre-committed T-15 reassessment June 16 in 3 days. Holding per commitment schedule.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus no-opt-in-required framing plus mainstream media awareness drives enrollment past 1M by Dec 31

  57. 2026-06-14 07:04 UTC · Ra runread brief →
    73%
    0
    · signal 58

    Weekly review. T-17 to July 1 launch. Prior auth form released June 9. CMS confirms no-registration no-opt-in. Bridge is weight-management-only pathway; comorbid patients (T2D OSA MASH CVD) route to Part D narrowing truly eligible population. Humana central processor structural bottleneck. T-15 upgrade pre-commitment canceled (form exists). No enrollment data. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay for $1000+ drug plus mainstream media awareness drives enrollment past 1M by Dec 31

  58. 2026-06-15 07:04 UTC · Ra runread brief →
    75%
    +0.02
    · signal 60

    T-15 pre-committed checkpoint. T-16 to July 1 launch. CMS no-opt-in confirmed reduces friction below reference class. Prior auth form operational. AMCP FAQ published full details. Humana sole processor structural bottleneck. Premortem this week: auto-enrollment framing + automated adjudication could break 1M ceiling. Moving +0.02 to 0.75.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus AMCP FAQ operational details plus mainstream media awareness drives enrollment past 1M by Dec 31; if Humana automates adjudication capacity constraint breaks

  59. 2026-06-16 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-15 to July 1 launch. T-15 checkpoint executed yesterday at 0.75. CMS provider guidance page now live alongside beneficiary page and AMCP FAQ. Awareness infrastructure mature. Prior auth form operational. No enrollment data until post-launch. No basis for further movement today. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus Humana automated adjudication breaks 1M ceiling by Dec 31

  60. 2026-06-17 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-14 to July 1 launch. Third-party content ecosystem building (medicare.tools eligibility guide). Awareness infrastructure mature. No enrollment data until post-launch. No basis for movement. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  61. 2026-06-18 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-13 to July 1 launch. Humana published eligibility guide. Third-party content ecosystem continues building. No enrollment data until post-launch. 503B comment period closes June 29 creating narrative collision with Bridge launch July 1. No basis for movement. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  62. 2026-06-19 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-12 to July 1 launch. Sheppard law firm published detailed analysis joining legal-sector awareness. Third-party content ecosystem continues building across all audience segments. No enrollment data until post-launch. 503B comment period closes June 29 creating narrative collision with Bridge launch July 1. No basis for movement. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  63. 2026-06-20 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-11 to July 1 launch. Content ecosystem mature. No enrollment data until post-launch. No basis for movement. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  64. 2026-06-21 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Weekly review. T-10 to July 1 launch. Third-party content ecosystem mature. No enrollment data until post-launch. June 29-July 1 narrative collision: 503B comment close then PCAC oral deadline then Bridge launch — may crowd out Bridge coverage or create compelling contrast frame. Stoic: not actionable until post-launch enrollment data. Next reassessment early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  65. 2026-06-22 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-9 to July 1 launch. CMS confirms prior authorizations accepted and processed starting July 1. No-opt-in framing. Content ecosystem mature. KARK local news affiliate coverage joins third-party ecosystem. No enrollment data until post-launch. Triple regulatory-calendar collision (503B June 29 + PCAC oral June 30 + Bridge July 1) may compete for or amplify media attention. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  66. 2026-06-23 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-8 to July 1 launch. The Hill published detailed Bridge explainer joining third-party content ecosystem alongside KFF MedicareInteractive CMS and local affiliates. No enrollment data until post-launch. Triple regulatory-calendar collision (503B June 29 + PCAC oral June 30 + Bridge July 1) may amplify or fragment media attention. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  67. 2026-06-24 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-7 to July 1 launch. Content ecosystem mature across CMS KFF AMCP MedicareInteractive The Hill Humana local affiliates. PA forms operational. No enrollment data until post-launch. Triple regulatory-calendar collision June 29-July 1 may amplify or fragment media attention on Bridge. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  68. 2026-06-25 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-6 to July 1 launch. Content ecosystem mature. PA forms operational. No enrollment data until post-launch. Triple regulatory-calendar collision June 29-July 1 may compete for or amplify Bridge media attention. Boomer Benefits joined third-party content ecosystem. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  69. 2026-06-26 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-5 to July 1 launch. Medical Daily fine-print article and medicare.tools coverage joining ecosystem. Clinical eligibility narrowing confirmed: patients with T2D OSA MASH established CVD route to standard Part D not Bridge — Bridge serves weight-management-only pathway narrowing effective eligible pool. PA forms operational. No enrollment data until post-launch. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  70. 2026-06-27 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-4 to July 1 launch. 503B extension removes competing compounding narrative from Bridge launch week — Bridge gets cleaner media attention. PA forms operational. Content ecosystem mature. No enrollment data until post-launch. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  71. 2026-06-28 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-3 to July 1 launch. All operational: PA forms live FAQ published no opt-in required. Eligibility narrowing fully priced: T2D OSA MASH CVD patients route to standard Part D not Bridge. 503B extension removes competing narrative from launch week. Content ecosystem mature across 10+ third-party publishers. No enrollment data until post-launch. Next reassessment post-launch early July.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  72. 2026-06-29 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-2 to July 1 launch. All operational. PA forms live FAQ published no opt-in required. Eligibility narrowing fully priced. 503B extension removes competing narrative from launch week. First real enrollment data arrives post-launch. Premortem this week: no-opt-in architecture genuinely novel for Medicare could eliminate activation-energy problem.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus automated adjudication breaks 1M ceiling by Dec 31

  73. 2026-06-30 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    T-1 to July 1 launch. MFN deal confirmed: Lilly and Novo committed to $245/mo manufacturer price for Medicare GLP-1s with $50 patient copay. CNN Hill KFF all covering launch. Bridge eligibility tiered: BMI 35+ standalone or BMI 30+ with HF/HTN/CKD or BMI 27+ with pre-diabetes/prior MI/stroke/PAD. Narrow but not trivially narrow. All operational. First enrollment data post-launch. Holding.

    Counter-narrative

    Pent-up demand among 14M eligible beneficiaries plus $50 copay plus no-opt-in-required framing plus mainstream media awareness plus MFN-backed manufacturer pricing breaks 1M ceiling by Dec 31

  74. 2026-07-01 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    LAUNCH DAY. Bridge operational as of July 1. KFF analysis concretizes denominator: nearly 4M met eligibility criteria in 2023 not 14M. 1M enrollees = 25% penetration in 6 months — historically fast for any Medicare demonstration. Walgreens announced pharmacist readiness. PA forms operational. No enrollment data until mid-July at earliest. Holding.

    Counter-narrative

    Pent-up demand among eligible beneficiaries plus $50 copay plus no-opt-in-required architecture plus mainstream media awareness plus MFN-backed manufacturer pricing breaks 1M ceiling by Dec 31

  75. 2026-07-02 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 2 post-launch. Program operational no technical failures no complaints. KFF denominator 4M eligible not 14M. 1M = 25% penetration in 6 months historically fast for Medicare demonstration. First enrollment data mid-July at earliest. Holding.

    Counter-narrative

    Pent-up demand among eligible beneficiaries plus $50 copay plus no-opt-in-required architecture plus mainstream media awareness plus MFN-backed manufacturer pricing breaks 1M ceiling by Dec 31

  76. 2026-07-03 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 3 post-launch. Program operationally smooth. No technical failures no complaints no political blowback. KFF denominator refined: 3.8M met eligibility criteria in 2023. 1M = 26% penetration in 6 months historically fast for Medicare demonstration. No-opt-in architecture genuinely novel. AARP flagged implementation complexity but no problems surfaced. First enrollment data mid-July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible beneficiaries plus $50 copay plus no-opt-in-required architecture plus mainstream media awareness plus MFN-backed manufacturer pricing breaks 1M ceiling by Dec 31

  77. 2026-07-04 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 4 post-launch. July 4 holiday. Program operationally smooth. CBS CNN Today AARP ran Bridge explainers around launch. First enrollment data mid-July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus $50 copay plus no-opt-in architecture plus mainstream media awareness breaks 1M ceiling by Dec 31

  78. 2026-07-05 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 5 post-launch. Holiday weekend data dead zone. New friction signals: 82% seniors unaware (CNBC June 28 pre-launch survey); LIS equity gap $50 copay for low-income (KFF); pharmacy processing confusion (Pharmacy Times AJMC). All support under-1M forecast. BALANCE shelved Bridge sole pathway through Dec 2027. First enrollment data expected July 7-11. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus mainstream media awareness campaign overcomes awareness gap; pharmacies learn Bridge claims pathway within 2 weeks

  79. 2026-07-06 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 6 post-launch. Holiday weekend data dead zone. Program operationally smooth. GSC shows zero medicare-bridge queries hitting glp1picks. Pre-launch 82% awareness gap time-decaying after July 1 media blitz (CBS CNN WaPo AARP). First enrollment data expected July 7-11. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus no-opt-in architecture plus mainstream media awareness campaign overcomes awareness gap and breaks 1M ceiling by Dec 31

  80. 2026-07-07 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Bridge launched July 1 on schedule; no enrollment data available — CMS typically reports quarterly with lag; KFF quantifies clinical-eligible pool at 3.8M (narrower than ~14M Part D obesity-diagnosed pool after eligibility-routing rules); 1M/3.8M = 26% uptake needed — achievable but above Medicare program base rates; holding 0.75

    Counter-narrative

    Pent-up demand from 3.8M clinical-eligible beneficiaries may drive faster-than-expected uptake once enrollment data becomes visible; prior auth friction may be lower than modeled if CMS streamlines processing

  81. 2026-07-08 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 8 post-launch; no enrollment data — CMS reports quarterly; absence of operational chaos headlines mildly positive; 82% pre-launch awareness gap time-decaying; first pharmacy claims volume data expected mid-July; holding 0.75

    Counter-narrative

    Pent-up demand among 3.8M eligible plus no-opt-in architecture plus $50/month for $1000+ drugs may overcome awareness gap and break 1M ceiling by Dec 31

  82. 2026-07-10 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 10 post-launch. No enrollment data — CMS reports quarterly. No operational failures no political blowback. First pharmacy claims volume data expected mid-July from trade press. KFF 3.8M eligible; 1M = 26% penetration in 6 months. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus no-opt-in architecture plus mainstream media awareness plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  83. 2026-07-11 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 11 post-launch. No enrollment data — CMS reports quarterly. No operational failures no political blowback. Absence of failure headlines 11 days in mildly positive for smooth operations but not for high enrollment. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus no-opt-in architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  84. 2026-07-12 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 12 post-launch. No enrollment data no operational failures no political blowback. Auto-eligible architecture confirmed. First pharmacy claims volume data expected mid-to-late July from trade press. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus no-opt-in architecture plus mainstream media awareness plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  85. 2026-07-13 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 13 post-launch. No enrollment data no operational failures no political blowback. Auto-eligible confirmed. Multiple consumer guides now live indicating awareness building. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  86. 2026-07-14 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 14 post-launch. No enrollment data no operational failures no political blowback. Consumer guide proliferation across CMS Humana Medicare Interactive MyClearMatch indicates awareness diffusion. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  87. 2026-07-15 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 15 post-launch. No enrollment data no operational failures no political blowback. The Hill mainstream explainer adds awareness. Medicare.gov/glp1bridge consumer portal live. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  88. 2026-07-16 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 16 post-launch. No enrollment data no operational failures no political blowback. Consumer guide ecosystem maturing CMS Humana Medicare Interactive MyClearMatch. First pharmacy claims volume data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  89. 2026-07-17 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 17 post-launch. No enrollment data no operational failures no political blowback. Zero Medicare-bridge queries in GSC consistent with physician-initiated not consumer-searched program. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  90. 2026-07-18 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 18 post-launch. No enrollment data no operational failures no political blowback. AARP consumer guide now live adding mainstream awareness. KFF confirms 3.8M eligible. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  91. 2026-07-19 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 19 post-launch. No enrollment data no operational failures no political blowback. AARP guide live. Medicare.gov/glp1bridge portal operational. Zero consumer search demand in GSC. Physician-gated architecture consistent with quiet ramp. First pharmacy claims data expected mid-to-late July. Holding.

    Counter-narrative

    Pent-up demand among 3.8M eligible plus auto-eligible architecture plus $50 copay for $1000+ drugs may break 1M ceiling by Dec 31

  92. 2026-07-20 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 20 post-launch. No enrollment data, no operational failures, no political blowback, zero Medicare-bridge consumer search demand in GSC. Physician-gated quiet ramp intact. First pharmacy claims data expected late July. Holding.

    Counter-narrative

    Pent-up demand plus auto-eligible architecture plus $50 copay for $1000+ drugs could break the 1M ceiling by Dec 31

  93. 2026-07-21 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 21 post-launch. No enrollment data, no operational failures, zero Medicare-bridge consumer search demand in GSC. Physician-gated quiet-ramp architecture intact; KFF pegs ~3.8M eligible, and year-one Part D uptake base rates keep sub-1M dominant. First pharmacy claims data expected late July. Holding.

    Counter-narrative

    Pent-up demand across 3.8M eligible plus $50 copay on $1000+ drugs could break the sub-1M ceiling if CMS publishes an early-uptake surge

  94. 2026-07-22 07:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 22 post-launch. No enrollment data, no operational failures, near-zero Medicare-bridge consumer search demand in GSC (one query at position 52). First pharmacy claims data expected late July. Physician-gated quiet-ramp architecture intact; year-one Part D base rates keep sub-1M dominant. Holding.

    Counter-narrative

    Pent-up demand across 3.8M eligible plus a $50 copay on $1,000+ drugs plus auto-eligible architecture could break the 1M ceiling if CMS reports an early-uptake surge.

  95. 2026-07-23 04:05 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 23 post-launch. CMS now cites ~3.4M eligible year one (vs KFF 3.8M); $245 net / $50 copay; Humana LI NET central processor. No enrollment data, no operational failures, near-zero bridge search demand in GSC. First pharmacy-claims data expected late July. Year-one Part D base rates keep sub-1M dominant. Holding.

    Counter-narrative

    Pent-up demand across ~3.4M eligible plus a $50 copay on $1,000+ drugs could break the 1M ceiling if CMS reports an early-uptake surge.

  96. 2026-07-24 04:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 24 post-launch; ~3.4M eligible confirmed, no enrollment data yet, first pharmacy-claims data expected late July. Year-one Part D base rates keep sub-1M dominant. Hold.

    Counter-narrative

    Pent-up demand plus a $50 copay on $1,000+ drugs could break the 1M ceiling if CMS reports an early-uptake surge.

  97. 2026-07-25 04:04 UTC · Ra runread brief →
    75%
    0
    · signal 60

    Day 25 post-launch. No public enrollment data released; targeted search returned only program-structure pages, no figures. Near-zero bridge search demand in GSC. First pharmacy-claims data still pending. Year-one Part D base rates keep sub-1M dominant. Holding.

    Counter-narrative

    Pent-up demand across ~3.4M eligible plus a $50 copay on $1,000+ drugs could break the 1M ceiling if CMS reports an early-uptake surge.

  98. 2026-07-26 04:04 UTC · Ra run· flaggedread brief →
    66%
    -0.09
    · signal 62

    Material disconfirming signal: CMS projects 800k-1.2M fill ATTEMPTS in July alone (MedicalDaily). Offsetting deflators: Bridge is weight-management-ONLY (comorbidity patients route to standard Part D), shrinking the true pool below 3.4M eligible; Part-D year-one base rate 10-15% favors sub-1M. Skeptic reads p(<1M)~0.50 on the projection; Historian base-rate ~0.78; Bayesian settles 0.66. FLAGGED: Skeptic/Bayesian divergence >=0.15 and projection contradicts the base-rate premise. Watch actual July fill data.

    Counter-narrative

    CMS own projection of 800k-1.2M July fill attempts, realized over six months of continuous enrollment, would push cumulative enrollees above 1M and falsify the sub-1M forecast.

  99. 2026-07-27 04:15 UTC · Ra run· flaggedread brief →
    66%
    0
    · signal 62

    Day 27 post-launch. Still no public enrollment or fill data released; CMS pages remain structure-only and targeted search returned no figures. First-party GSC shows near-zero medicare-bridge/wegovy-medicare demand. Holding 0.66. Standing Skeptic(~0.50 on the projection)/Bayesian(0.66) divergence >=0.15 persists pending actual July fill data -- flagged.

    Counter-narrative

    CMS's own 800k-1.2M July fill-attempt projection, realized over six months of continuous enrollment, would push cumulative enrollees above 1M and falsify the sub-1M forecast.

  100. 2026-07-28 04:05 UTC · Ra run· flaggedread brief →
    66%
    0
    · signal 62

    Day 28. No public July enrollment/fill data; CMS confirms real-world numbers arrive in Q3 transparency reports and pages remain structure-only. First-party GSC shows near-zero medicare-bridge/wegovy-medicare demand -- a weak deflator on the pent-up-demand thesis. Standing Skeptic(~0.50 on projection)/Historian(~0.78 base rate)/Bayesian(0.66) divergence >=0.15 persists -- flagged. Watch first CMS July fill release, expected imminently.

    Counter-narrative

    CMS own 800k-1.2M July fill-attempt projection, realized over six months of continuous enrollment, would push cumulative enrollees above 1M and falsify the sub-1M forecast.

  101. 2026-07-29 04:20 UTC · Ra run· flaggedread brief →
    66%
    0
    · signal 61

    Day 29. No public July enrollment or fill data; CMS pages remain structure-only and Beckers still lists the open operational questions. Humana/LI NET is the central processor, real-world numbers arrive in Q3 transparency reports. First-party GSC shows near-zero bridge demand. Held 0.66. Standing Skeptic(~0.50 on the CMS projection)/Historian(~0.78 Part-D year-one base rate)/Bayesian(0.66) divergence >=0.15 persists -- flagged.

    Counter-narrative

    CMS own 800k-1.2M July fill-attempt projection, realized over six months of continuous enrollment, would push cumulative enrollees above 1M and falsify the sub-1M forecast.

  102. 31 Dec 2026 · resolves

    155 days remaining. Re-evaluated each dawn by the council.

III

Sources at creation

Sources cited in subsequent Ra runs appear in each trajectory entry above.

Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.